Hologic, Inc. [NASDAQ: HOLX] disclosed that it has finally unveiled the Novodiag system for on-demand testing of infectious diseases and antimicrobial resistance in Europe. The decision to unveil Novodiag came after the purchase of Mobidiag Oy by HOLX in June 2021 and will bring the advantages of the Novodiag system to a vast variety of customers in Europe.
HOLX believed that its decision to purchase Mobidiag was to bolster its international diagnostics business. The launch of the Novodiag system has proven the commitment of the firm. The launch of the Novodiag system to its diagnostic molecular scalable solutions portfolio will provide more a broad option of solutions to customers in Europe that fulfill their demands, from single patient rapid testing to population-level screening.
The Novodiag system integrates real-time PCR and microarray capabilities. This integration allowed the multiple pathogens to be recognized in a single sample. Therefore, it delivers a simple and fast way to locate sufferers who are most at risk with targeted and syndromic on-demand testing.
Furthermore, its CE-IVD test menu features highly multiplexed on-demand assays noticing gastrointestinal infections and antibiotic resistance, as well as a targeted assay for the identification of SARS-CoV-2. A strong pipeline is also in development. The Novodiag system is a high multiplex technology that is precision-engineered for easiness, precision, and affordability across a comprehensive and mounting menu of high and low-plex assays.